文献速递临床试验与 GCP基础与转化研究

透明质酸间隔物注射减少近距离放疗加速部分乳腺照射皮肤毒性的随机对照试验:研究方案

A randomized controlled trial testing a hyaluronic acid spacer injection for skin toxicity reduction of brachytherapy accelerated partial breast irradiation (APBI): a study protocol.
PubMed 文献 · Trials · 2018-12-17

该平行组单中心随机对照试验纳入符合国际指南的早期乳腺癌保乳术后患者,随机在永久性乳腺种子植入(PBSI)后于皮下注射透明质酸间隔物,以评估其降低皮肤剂量和晚期皮肤毒性(毛细血管扩张)的效果。主要终点为两年时盲法评估的毛细血管扩张率,样本量230例。

要点

  • PBSI后皮下注射透明质酸间隔物可增加治疗体积与皮肤间0.5-1 cm空间。
  • 主要终点为两年时盲法评估的毛细血管扩张率,使用Bentzen 4点量表。
  • 样本量230例,假设间隔物可将毛细血管扩张率从22.4%降至7.7%。

核心结论

  • 该研究旨在验证皮下注射透明质酸间隔物可降低PBSI患者的皮肤剂量及后续皮肤毒性。

研究设计与样本

  • 平行组、单中心、随机对照试验,计划样本量230例,并考虑10%失访率。

主要发现

  • 原文为研究方案,未报告试验结果;主要终点为两年时盲法评估的毛细血管扩张率。

关键数值与推荐

  • 入选标准包括年龄≥50岁、组织学证实非小叶乳腺癌和/或导管原位癌(DCIS)、肿瘤大小≤3 cm、淋巴结阴性且PBSI技术上可行。
  • 排除标准包括新辅助化疗、淋巴血管侵犯和透明质酸过敏。
  • 干预组在PBSI术后超声引导下皮下注射4-10 cc可降解透明质酸(Barrigel™或Restylane SubQ®),创建额外0.5-1 cm空间。
  • 主要终点为两年时盲法评估的毛细血管扩张率(Bentzen 4点量表),采用Fisher精确检验比较组间差异。
  • 基于既往研究两年毛细血管扩张率22.4%,预期间隔物可降至7.7%。

临床怎么用

  • 若研究证实有效,皮下间隔物注射可能用于PBSI及其他乳腺近距离放疗或机器人放射外科中保护皮肤。

局限性

  • 原文为研究方案,尚未提供干预效果数据;单中心设计可能影响外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accelerated partial breast irradiation (APBI) is a treatment option for selected early stage breast cancer patients. Some APBI techniques lead to skin toxicity with the skin dose as main risk factor. We hypothesize that a spacer injected between the skin and target volume reduces the skin dose and subsequent toxicity in permanent breast seed implant (PBSI) patients. METHODS: In this parallel-group, single-center, randomized controlled trial, the effect of a subcutaneous spacer injection on skin toxicity among patients treated with PBSI is tested. Eligibility for participation is derived from international guidelines for suitable patients for partial breast radiotherapy, e.g. women aged ≥ 50 years with a histologically proven non-lobular breast carcinoma and/or ductal carcinoma in situ (DCIS), tumor size ≤ 3 cm, node-negative, and PBSI technically feasible. Among exclusion criteria are neoadjuvant chemotherapy, lymphovascular invasion, and allergy for hyaluronic acid. For the patients allocated to receive spacer, after the PBSI procedure, 4-10 cc of biodegradable hyaluronic acid (Barrigel™, Palette Life Sciences, Santa Barbara, CA, USA or Restylane SubQ®, Galderma Benelux, Breda, the Netherlands) is injected directly under the skin using ultrasound guidance to create an extra 0.5-1 cm space between the treatment volume and the skin. The primary outcome is the rate of telangiectasia at two years, blindly assessed using Bentzen's 4-point scale. Secondary outcomes include: local recurrence; disease-free and overall survival rates; adverse events (pain, redness, skin/subcutaneous induration, radiation dermatitis, pigmentation, surgical site infection); skin dose; cosmetic and functional results; and health-related quality of life. A Fisher's exact test will be used to test differences between groups on the primary outcome. Previous studies found 22.4% telangiectasia at two years. We expect the use of a spacer could reduce the occurrence of telangiectasia to 7.7%. A sample size of 230 patients will allow for a 10% lost to follow-up rate. DISCUSSION: In this study, the effect of a subcutaneous spacer injection on the skin dose, late skin toxicity, and cosmetic outcome is tested in patients treated with PBSI in the setting of breast-conserving therapy. Our results will be relevant for most forms of breast brachytherapy as well as robotic radiosurgery, as skin spacers could protect the skin with these other techniques. TRIAL REGISTRATION: Netherlands Trial Register, NTR6549 . Registered on 27 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Struik GM, Godart J, Verduijn GM, et al. A randomized controlled trial testing a hyaluronic acid spacer injection for skin toxicity reduction of brachytherapy accelerated partial breast irradiation (APBI): a study protocol. Trials. 2018. PMID: 30558672. doi:10.1186/s13063-018-3035-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。